Latest news with #AclarisTherapeutics
Business Insider
3 days ago
- Business
- Business Insider
Aclaris Therapeutics assumed with an Overweight at Piper Sandler
Piper Sandler analyst Biren Amin assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating and $6 price target The shares are currently trading below the company's cash position with three data readouts over the next 12-15 months, the analyst tells investors in a research note. The firm believes each readout offers 'meaningful upside' to Aclaris shares. Piper believes the company's lead program, bosakitug, has demonstrated proof of efficacy activity in a small Phase 2a study in moderate to severe atopic dermatitis. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
28-05-2025
- Business
- Yahoo
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June. On Wednesday June 4, 2025, at 10:30 AM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during Jefferies Global Healthcare Conference in New York, NY. On Wednesday June 11, 2025, at 1:20 PM EDT, Dr. Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, FL. A live and archived webcast of both events will be accessible on the Events page of The webcasts will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn. Aclaris Therapeutics Contact: Will RobertsSenior Vice PresidentCorporate Communications and Investor Relations(484) 329-2125wroberts@ Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June. On Wednesday June 4, 2025, at 10:30 AM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during Jefferies Global Healthcare Conference in New York, NY. On Wednesday June 11, 2025, at 1:20 PM EDT, Dr. Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, FL. A live and archived webcast of both events will be accessible on the Events page of The webcasts will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn. Aclaris Therapeutics Contact: Will RobertsSenior Vice PresidentCorporate Communications and Investor Relations(484) 329-2125wroberts@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Globe and Mail
21-05-2025
- Business
- Globe and Mail
Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Common Warts pipeline constitutes 5+ key companies continuously working towards developing 5+ Common Warts treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. ' Common Warts Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Common Warts Market. The Common Warts Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Common Warts Pipeline Report: Companies across the globe are diligently working toward developing novel Common Warts treatment therapies with a considerable amount of success over the years. Common Warts companies working in the treatment market are Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others, are developing therapies for the Common Warts treatment Emerging Common Warts therapies in the different phases of clinical trials are- CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others are expected to have a significant impact on the Common Warts market in the coming years. In May 2025, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced progress in its late-stage development pipeline, highlighted by the completion of an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for VP-315, the company's investigational treatment for basal cell carcinoma. Additionally, Verrica is making strides toward launching a global Phase 3 clinical program for VP-102/YCANTH, its treatment candidate for common warts, in collaboration with its partner, Torii Pharmaceutical. In February 2025, Nielsen BioSciences, Inc., a privately held biopharmaceutical company headquartered in San Diego, announced the successful enrollment of the final participant in its Phase 3 clinical trial, CFW-3A. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of CANDIN® (Candida albicans Skin Test Antigen for Cellular Hypersensitivity) for treating common warts (Verruca vulgaris) in both adolescents and adults. It's important to note that CANDIN is not yet approved for this indication. In December 2024, Veradermics was a late-stage clinical biopharmaceutical company specializing in aesthetics and dermatology, dedicated to developing innovative therapies for common skin disorders. Its leading product, VDPHL01, is a non-hormonal oral treatment currently being tested for androgenetic alopecia (AGA) and pattern hair loss (PHL) in both male and female patients. Additionally, the company's pipeline features treatments targeting widespread dermatological conditions like warts and molluscum contagiosum. In August 2024, Verrica Pharmaceuticals reported encouraging new findings from its Phase 2 trial of the oncolytic peptide VP-315 for basal cell carcinoma treatment. With positive safety and efficacy outcomes, the company sees VP-315 as a potential first-line therapy for this cancer type. Comprehensive results will be shared at an upcoming KOL event. Furthermore, Verrica has revised its agreement with Torii Pharmaceutical Inc. Ltd., supporting the progression of YCANTH into Phase 3 trials for common warts. Addressing a significant unmet need in dermatology, YCANTH has the potential to become a new standard of care, as no FDA-approved treatments currently exist for common warts. In May 2024, Verrica Pharmaceuticals announced an update to its collaboration and licensing agreement with Torii Pharmaceutical Co. Ltd. to jointly fund the global Phase 3 clinical trial for YCANTH® targeting common warts. According to the revised terms, both companies will equally share the trial expenses, with Torii covering Verrica's share by offsetting future payments related to regulatory milestones and sales of YCANTH for molluscum contagiosum and common warts in Japan. Furthermore, Torii will make an $8.0 million milestone payment to Verrica upon dosing the first patient in Japan, with the Phase 3 trial expected to commence in the first half of 2025. Common Warts Overview Common warts are small, noncancerous skin growths caused by the human papillomavirus (HPV). They typically appear on the hands, fingers, or other areas prone to minor cuts and abrasions. Common warts have a rough, grainy texture and are often flesh-colored, with tiny black dots (clotted blood vessels) on the surface. Emerging Common Warts Drugs Under Different Phases of Clinical Development Include: CANDIN: Nielsen BioSciences/Maruho VP-102: Verrica Pharmaceutical FIT039: Kino Pharma/ Iwaki Pharmaceutical A-101: Aclaris Therapeutics, Inc. KNP2002: KinoPharma Inc. 10% EISO: ViroXis Corporation CLS006: Maruho Co., Ltd. VDMN-21: Veradermics, Inc. Resiquimod: Graceway Pharmaceuticals, LLC Imiquimod: MEDA Pharma Picato: LEO Pharma Common Warts Route of Administration Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Parenteral Intravenous Subcutaneous Topical Common Warts Molecule Type Common Warts Products have been categorized under various Molecule types, such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Common Warts Pipeline Therapeutics Assessment Common Warts Assessment by Product Type Common Warts By Stage and Product Type Common Warts Assessment by Route of Administration Common Warts By Stage and Route of Administration Common Warts Assessment by Molecule Type Common Warts by Stage and Molecule Type DelveInsight's Common Warts Report covers around 5+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Common Warts product details are provided in the report. Download the Common Warts pipeline report to learn more about the emerging Common Warts therapies Some of the key companies in the Common Warts Therapeutics Market include: Key companies developing therapies for Common Warts are - Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Aclaris Therapeutics, and others. Common Warts Pipeline Analysis: The Common Warts pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Common Warts with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Common Warts Treatment. Common Warts key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Common Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Common Warts market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Common Warts Pipeline Market Strengths The rising prevalence of warts is encourages companies in the life sciences industry to focus on research and development of new drugs for warts treatment. There is a continuous need for new, innovative therapeutic approaches for better treatment outcomes. An increase in emerging new drugs for the treatment of warts will lead to better patient outcomes in the coming years. Common Warts Pipeline Market Opportunities Recent studies have shown the safe and efficacious role of Zinc supplementation in warts clearance, particularly for patients who have not responded to treatments previously. Secondary research on the warts therapeutics market suggests that the market is saturated with limited drug opportunities providing the key Pharma players a successful domain to work with utmost robustness Scope of Common Warts Pipeline Drug Insight Coverage: Global Key Common Warts Companies: Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma/ Iwaki Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma Inc., ViroXis Corporation, Maruho Co., Ltd., Veradermics, Inc., Graceway Pharmaceuticals, LLC, MEDA Pharma, LEO Pharma, and others Key Common Warts Therapies: CANDIN, VP-102, FIT039, A-101, KNP2002, 10% EISO, CLS006, VDMN-21, Resiquimod, Imiquimod, Picato, and others Common Warts Therapeutic Assessment: Common Warts current marketed and Common Warts emerging therapies Table of Contents 1. Common Warts Report Introduction 2. Common Warts Executive Summary 3. Common Warts Overview 4. Common Warts- Analytical Perspective In-depth Commercial Assessment 5. Common Warts Pipeline Therapeutics 6. Common Warts Late Stage Products (Phase II/III) 7. Common Warts Mid Stage Products (Phase II) 8. Common Warts Early Stage Products (Phase I) 9. Common Warts Preclinical Stage Products 10. Common Warts Therapeutics Assessment 11. Common Warts Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Common Warts Key Companies 14. Common Warts Key Products 15. Common Warts Unmet Needs 16 . Common Warts Market Drivers and Barriers 17. Common Warts Future Perspectives and Conclusion 18. Common Warts Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
10-05-2025
- Business
- Yahoo
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$1.46m (down 39% from 1Q 2024). Net loss: US$15.1m (loss narrowed by 11% from 1Q 2024). US$0.12 loss per share (improved from US$0.24 loss in 1Q 2024). Our free stock report includes 3 warning signs investors should be aware of before investing in Aclaris Therapeutics. Read for free now. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 59%. Earnings per share (EPS) exceeded analyst estimates by 28%. Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry. The company's shares are down 13% from a week ago. Be aware that Aclaris Therapeutics is showing 3 warning signs in our investment analysis and 2 of those can't be ignored... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
